It was déja vu, but not the same. In August 2002, when ViroPharma Inc.'s deal with Aventis Pharmaceuticals Inc. to develop Picovir (pleconaril) for the common cold ended - the arrangement was terminated by mutual consent, and ViroPharma's stock fell more than 25 percent - CEO Michel de Rosen told investors: "Today is the day when we begin to look forward again." (BioWorld Financial Watch)

SAN FRANCISCO - Biotechnology's famed "H&Q" meeting every January is known less as a hotbed of ideas than the place where financiers come together with biotechnology leaders for dealmaking - but one panel discussion challenged at least some attendees in the packed room to reconsider their ideas. (BioWorld Financial Watch)